BioCentury
ARTICLE | Distillery Therapeutics

Cancer

August 29, 2017 6:04 PM UTC

Patient sample, cell culture and mouse studies suggest inhibiting S100A4 or depleting S100A4-expressing cells could help treat glioblastoma multiforme (GBM) and other gliomas. In samples from glioma patients, high tumor levels of S100A4 were associated with poor overall survival. In tumorspheres derived from a mouse model of glioma and GBM patients, knockdown of S100A4 decreased tumor cell viability compared with normal S100A4 expression. In a mouse model of glioma, knockdown of S100A4 or depletion of S100A4-expressing tumor cells decreased tumor growth compared with normal S100A4 expression or no treatment. Next steps could include testing S100A4 inhibitors in glioma models...